YuanBio Venture Capital, also known as bioVenture, has filed with the US Securities and Exchange Commission (SEC) to raise a new fund that is likely to continue to invest in life sciences and healthcare companies.
The Chinese venture capital firm, which focuses on early and growth-stage investments, did not specify the target amount for YuanBio Venture Capital II LP but said the offering will not last more than one year.
